US Pharm. 2014;39(4):7.

London, UK—Results of a phase II study published in The Lancet suggest that simvastatin, a generic cholesterol-lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS), which is currently untreatable. Findings from the MS-STAT trial showed that a high, daily dose (80 mg) of simvastatin was safe, well tolerated, and slowed brain atrophy (shrinkage) by 43% over 2 years compared with placebo. Longitudinal studies suggest that atrophy progression is linked with disability. To date, no licensed drugs have shown a convincing impact on this later stage of the disease. Further phase III studies will be required to measure the effect of simvastatin on sustained disability in patients with MS.

To comment on this article, contact